logo

anti-Bacterial Innovative Vaccine Training Network.

Sector: Hospital • Location: Ireland, Italy, United Kingdom, Spain, Germany, Switzerland, Hungary, Belgium

Source: EU Funding & Tenders Portal

Project
Ended

BactiVax (anti-Bacterial Innovative Vaccine Training Network) is a European training network (ETN) that will provide high-level training in vaccinology to a new generation of 15 high-achieving, early-stage researchers (ESRs). This innovative ETN uniquely blends cutting-edge research training, non-academic placements and transferable skills. It will develop strong entrepreneurial and creative minds

Project Information FAQ

Project Information

4 Q
The project “anti-Bacterial Innovative Vaccine Training Network.” is an infrastructure initiative in the Hospital sector, located in Ireland, Italy, United Kingdom, Spain, Germany, Switzerland, Hungary, Belgium. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ended

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

BactiVax (anti-Bacterial Innovative Vaccine Training Network) is a European training network (ETN) that will provide high-level training in vaccinology to a new generation of 15 high-achieving, early-stage researchers (ESRs). This innovative ETN uniquely blends cutting-edge research training, non-academic placements and transferable skills. It will develop strong entrepreneurial and creative mindsets. BactiVax will train ESRs in a broad range of transferable skills enabling them to thrive in careers in vaccine research within academia and/or industry through discovery, development, and delivery of innovative therapeutic and prophylactic vaccines. The World Health Organisation has identified antimicrobial resistance (AMR) as one of the three greatest threats to mankind. There is a urgent need to train innovative ESRs in the development of new vaccines against AMR infections. BactiVax will tackle the societal challenge caused by the emergence of AMR pathogens and have significant impact on pathogens causing chronic, life-threatening respiratory and/or systemic infections. BactiVax training will cover critical areas of vaccinology from early antigen discovery to optimisation of host response and delivery of vaccine antigens. It will also encompass the increasing problem of vaccine hesitancy in its public engagement. The specific research objectives are to: 1) Identify novel, protective vaccine antigens against target pathogens; 2) Optimise the host response to vaccines; 3) Optimise vaccine delivery; 4) Lead on vaccine advocacy. BactiVax includes 2 SME beneficiaries, a multinational vaccine company and 4 SMEs as partners all of whom are involved in training, entrepreneurship, commercial vaccine development and vaccine antigen processing. All ESRs will have secondments in non-academic environment to enhance their exposure to the commercial. Overall, BactiVax will provide ESRs with rich experience and advanced multidisciplinary skills in the cutting edge area of vaccines

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data